Purpose of Review As the prevalence of individuals with recovered coronavirus disease 2019 (COVID-19) increases, determining if and when organs from these donors can be safely used is an important priority. We examined current knowledge of outcomes of transplant using donors with recovered COVID-19. Recent Findings A literature search of PubMed and Google scholar databases was conducted to identify articles with terms “SARS-CoV2,” “COVID-19,” “donor recovered,” and “transplantation” published through 08/10/2021. We identified 25 reports detailing 94 recipients of both abdominal and thoracic transplants from donors with both prior and active COVID-19 infection. Rates of transmission to the recipient and of transplanted organ dysfunction were low among reports of donors with prior COVID-19 infection. End organ dysfunction and transmission were more common with active infection, although few reports are available. Standardized reporting is needed to better assess the impact of donor symptomatology, cycle thresholds, and individual recipient risk factors on postoperative outcomes. Summary Available reports suggest that transplantation from COVID-19 donors may be feasible and safe, at least in short term follow-up. Nevertheless, there is a need for standardized testing and management protocols which should be tailored for available resources. While increased availability of COVID-19 vaccinations will mitigate risks of donor-derived COVID-19 and simplify management, continued vigilance is warranted during the ongoing public health emergency.

Post-COVID-19 mucormycosis has been exclusively reported in general population ¹ but the data is scarce in transplantation.². ³ Herein we report two cases of post-COVID-19 mucormycosis (Table 1) in renal transplant recipients who were admitted at IKDRC-ITS which is a high-volume transplant center in India. The first case was a 47-year aged gentleman transplanted 17 years ago. He developed diabetes 1.5 years back and was on oral hypoglycemic drugs (OHA) with well controlled blood sugars.

Background: There is a scarcity of data comparing the consequences of first and second COVID‐19 waves on kidney transplant recipients (KTRs) in India.Methods: We conducted a single‐centre retrospective study of 259 KTRs with COVID‐19 to compare first wave (March 15–December 31 2020, n = 157) and second wave (April 1–May 31 2021, n = 102).Results: KTRs during second wave were younger (43 vs. 40 years;p‐value .04) and also included paediatric patients (0 vs. 5.9%;p‐value .003). Symptoms were milder during the second wave (45 vs. 62.7%;p‐value .007); COVID‐19 positive patients had less frequent cough (32 vs. 13.8%;p‐value .001), fever was less frequent (58 vs. 37%;p‐value .001), and we observed fewer co‐morbidities (11 vs. 20.6%;p‐value .04). The percentages of neutrophils (77 vs. 83%;p‐value .001) and serum ferritin (439 vs. 688;p‐value .0006) were higher during second wave, while lymphocyte counts were reduced (20 vs. 14%;p‐value .0001). Hydroxychloroquine (11 vs. 0%;p‐value .0001) and tocilizumab (7 vs. 0%;p‐value .004) were more frequently prescribed during first wave, while utilization of dexamethasone (6 vs. 27%;p‐value .0001) and remdesivir (47 vs. 65%;p‐value .03) increased during the second wave. Mucormycosis (1.3 vs. 10%;p‐value .01) and ICU admissions (20 vs. 37.2%;p‐value .002) were more frequent during second wave. The 28‐day mortality rate (9.6 vs. 10%;p‐value 1) was not different.Conclusions: There has been a different clinical spectrum of COVID‐19 amongst KTR with similar mortality between the two waves at a large Indian transplant centre.